Research compound supplied in Australia by Pulse Biolabs. Available in 15mg.
The first dual-receptor compound to reach this stage of investigation. It reset what the category was measuring against.
Tirzepatide, development code LY3298176, is a synthetic 39-amino-acid peptide that acts as an agonist at both the GIP and GLP-1 receptors. It is described in the literature as the first compound of the dual-incretin class. Receptor occupancy analysis characterises it as an imbalanced agonist, engaging the GIP receptor to a greater degree than the GLP-1 receptor.
Read the full research note →Every batch is supplied with third-party analytical testing. Third-party test results are provided for informational purposes only. Pulse Biolabs undertakes rigorous verification of all testing data against batch records through independent sources; results are representative of the manufacturer batch but may not reflect every individual sample. For research use only.
View Tirzepatide test documents →
Lyophilised material is stored refrigerated and protected from light. Reconstitution requires bacteriostatic water, which is listed separately under Essentials. Once reconstituted, material is kept refrigerated.
| Presentation | Code | Status | Price |
|---|---|---|---|
| 15mg | TR15 | In stock | $110 |